JPH07145A - Composition of butyric acid bacterium - Google Patents
Composition of butyric acid bacteriumInfo
- Publication number
- JPH07145A JPH07145A JP3169965A JP16996591A JPH07145A JP H07145 A JPH07145 A JP H07145A JP 3169965 A JP3169965 A JP 3169965A JP 16996591 A JP16996591 A JP 16996591A JP H07145 A JPH07145 A JP H07145A
- Authority
- JP
- Japan
- Prior art keywords
- butyric acid
- glucomannan
- composition
- acid bacterium
- agar
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
【０００１】[0001]
【産業上の利用分野】本発明は、製剤的およびバイオア
ベイラビリティーの観点から優れた効果を示す酪酸菌組
成物に関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a butyric acid bacterium composition exhibiting excellent effects from the viewpoint of formulation and bioavailability.
【０００２】[0002]
【従来の技術】酪酸菌、とりわけクロストリジウム・ブ
チリカム・ミヤイリ５８８は、１９３５年、宮入近治氏
が発見し〔千葉医学会誌１３ ２３１１〜２３１５（１
９３５）〕、その後、多くの研究者によって、本菌が各
種の食中毒起因菌に対し強くかつ安定に拮抗することが
見出された〔千葉医学会誌１３ ２１４１〜２１６１
（１９３５）〕、千葉大学腐敗研究所報告1 ２７〜５３
（１９４８）、千葉大学腐敗研究所報告1 ５４〜５９
（１９４８）、千葉大学腐敗研究所報告2 ４３〜５０
（１９４９）〕。また臨床においても急性もしくは慢性
腸炎、赤痢、疫痢、消化不良症等さまざまな消化器官系
の疾患に対して有効であることが示された〔臨床内科4
９７３〜９８０（１９３５）、新薬と臨床２５ １５０
５〜１５０９（１９７６）〕。BACKGROUND OF THE INVENTION Butyric acid bacteria, especially Clostridium butyricum Miyairi 588, were discovered in 1935 by Mr. Konji Miyairi [Chiba Medical Society 13 2311-2315 (1
935)], and then, many researchers found that this bacterium strongly and stably antagonizes various food poisoning-causing bacteria [Chiba Medical Journal 13 2141-2161].
(1935)], Chiba University Corruption Research Institute Report 127-53
(1948), Chiba University Corruption Research Institute Report 1 54-59
(1948), Chiba University Corruption Research Institute Report 243-50
(1949)]. In addition, it has been clinically shown to be effective against various digestive system diseases such as acute or chronic enteritis, dysentery, plague, dyspepsia [Clinical internal medicine 4
973-980 (1935), New drugs and clinical 25 150
5-1509 (1976)].
【０００３】[0003]
【発明が解決しようとする課題】一方、近年、海外渡航
者が増大し、これにともなって発展途上国への旅行者の
間で、いわゆる旅行者下痢症が重要な問題となってきて
いる。これは旅行時に種々の腸管病原体の感染を受け、
多くは下痢を主症状とする急性胃腸炎である。それら腸
管病原体のなかで、とりわけ毒素原性大腸菌により感染
発症するケースが多く、この毒素原性大腸菌下痢症に対
して、酪酸菌が有効であることが基礎的な実験において
示されている〔薬理と治療１４６０７３〜６０８０（１
９８６）、薬理と治療１４ ４６５１〜４６５５（１９
８６）、ジャパニーズ・ジャーナル・オブ・ファーマコ
ロジー(Japan. J. Pharmacol．）５０ ４９５〜４９８
（１９８９）〕。On the other hand, in recent years, the number of overseas travelers has increased, and so-called traveler's diarrhea has become an important issue among travelers to developing countries. It is infected by various enteric pathogens during travel,
Most are acute gastroenteritis with diarrhea as the main symptom. Among these intestinal pathogens, there are many cases in which infection is caused by toxogenic Escherichia coli, and basic experiments have shown that butyric acid bacteria are effective against this toxogenic Escherichia coli diarrhea. And treatment 146073-6080 (1
986), Pharmacology and Treatment 14 4651-4655 (19)
86), Japanese Journal of Pharmacology (Japan. J. Pharmacol.) 50 495-498.
(1989)].
【０００４】また近年、抗菌スペクトルが広く、且つ抗
菌活性の強い抗生剤が次々と臨床に登場し、これに伴っ
て抗生剤起因性の大腸炎、下痢症が重要な問題となって
きた。これは投与抗生剤により宿主と生理的に密接に係
わっている腸内フローラが破壊され、抗生剤耐性の特定
細菌、例えばマイナーポピュレーションであるクロスト
リジウム・ディフィシル（Clostridium difficile)が顕
在化し、その産生する毒素によってもたらされるもの
で、高熱、白血球増多、低蛋白血症を伴い、腹痛、下
痢、血便等の激しい大腸炎症状を呈し、時に重篤な転帰
をとる場合がある。このような薬剤による大腸炎、下痢
症に対しても酪酸菌が有効であることが、基礎的実験
〔日本細菌学雑誌４３ ８２９〜８３５（１９８
８）〕、および臨床〔小児科臨床４１ ２４０９〜２４
１４（１９８８）〕において明らかとなってきた。In recent years, antibiotics having a broad antibacterial spectrum and a strong antibacterial activity have been successively introduced into the clinic, and accordingly, colitis and diarrhea caused by antibiotics have become important problems. This is because the administered antibiotics destroy the intestinal flora that is physiologically closely related to the host, and specific antibiotic-resistant bacteria, such as the minor population Clostridium difficile, are manifested and produced. It is caused by a toxin, which is accompanied by high fever, leukocytosis, hypoproteinemia, and severe colitis symptoms such as abdominal pain, diarrhea, and bloody stool, and sometimes has a serious outcome. It was found that butyric acid bacteria were effective against colitis and diarrhea caused by such drugs as a basic experiment [Japanese Journal of Bacteriology 43 829-835 (198).
8)], and clinical [pediatric clinical 41 2409-24
14 (1988)].
【０００５】これらの例にとどまることなく、酪酸菌は
さまざまな消化器疾患の他、便通促進、腸上皮細胞の修
復、大腸における水の再吸収等の働きをすることはすで
に周知の事柄である。Not limited to these examples, it is already well known that butyric acid bacteria act not only in various digestive diseases but also in promoting bowel movements, intestinal epithelial cell repair, water reabsorption in the large intestine, and the like. .
【０００６】一方、グルコマンナンは、コンニャクや百
合根等から調製されるダイエタリーファイバー（食物繊
維）であり、粘質物を多量に含み、人の消化酵素で消化
分解されず、故に吸収されない低カロリーな多糖体とし
て知られている。摂取されたグルコマンナンは、高分子
架橋体の中に大量の水分とともに塩分や脂質、その他有
害な細菌代謝物等を取り込んで膨潤し体外へ***され
る。このようなことから、グルコマンナンは腸の機能を
正常に働かせ、便通を促したり、血中コレステロールを
低下したり、また栄養過多による肥満者に対して、満腹
感を与え肥満の改善効果等があるとされている。さらに
近年、大腸癌の発生と食物繊維摂取との相関が疫学的に
明らかとなり、この種の食物繊維がその予防に有効とさ
れ、重要性が見直されつつある。[0006] On the other hand, glucomannan is a dietary fiber (dietary fiber) prepared from konjak, lily root, etc., contains a large amount of mucilage, is not digested and decomposed by human digestive enzymes, and is therefore not a low calorie. It is known as a polysaccharide. Ingested glucomannan takes in salt, lipid, and other harmful bacterial metabolites together with a large amount of water in the crosslinked polymer, swells, and is excreted outside the body. From these things, glucomannan has a normal intestinal function, promotes bowel movements, lowers blood cholesterol, and has the effect of improving obesity by giving a feeling of fullness to obese persons due to overnutrition. It is said that there is. Furthermore, in recent years, the correlation between the occurrence of colorectal cancer and dietary fiber intake has been clarified epidemiologically, and this type of dietary fiber is considered effective for its prevention, and its importance is being reviewed.
【０００７】[0007]
【課題を解決するための手段】本発明者等は、この優れ
た生理的特性を有するグルコマンナンと酪酸菌との組成
物について、製剤学的ならびにバイオアベイラビリティ
ーの観点から、鋭意検討を重ねた結果、本組成物が極め
て有用性の高いことが明らかとなり、本発明の完成をみ
た。即ち、本発明の要旨は、酪酸菌を代表する整腸生菌
と、グルコマンナンとからなる酪酸菌組成物にある。[Means for Solving the Problems] The inventors of the present invention have made extensive studies on the composition of glucomannan and butyric acid bacterium having this excellent physiological property from the viewpoints of pharmaceutical and bioavailability. As a result, it became clear that the present composition was extremely useful, and the present invention was completed. That is, the gist of the present invention resides in a butyric acid bacterium composition composed of a live intestinal bacterium representative of butyric acid bacterium and glucomannan.
【０００８】本発明で用いることができる酪酸菌は、例
えば、Clostridium butyricum NIP１００６（微工研菌
寄第１１８６８号）、Clostridium butyricum NIP １０
１５（微工研菌寄第１１８６９号）、Clostridium buty
ricum NIP １０１７（微工研菌寄第１１８７０号）であ
り、とくに、クロストリジウム・ブチリカム・ミヤイリ
５８８（微工研菌寄第２７８９号）が好ましい。The butyric acid bacterium which can be used in the present invention is, for example, Clostridium butyricum NIP1006 (Ministry of Industrial Science and Technology No. 11868), Clostridium butyricum NIP10.
15 (Microtechnology Research Institute, No. 11869), Clostridium buty
ricum NIP 1017 (Ministry of Microbiology Research No. 11870), and particularly preferred is Clostridium butyricum Miyairi 588 (Ministry of Microbiology Research No. 2789).
【０００９】一般に、酪酸菌の培養液から遠心分離法に
より収穫した酪酸菌ペーストはこの状態で乾燥した場合
は灰褐色の不定形のブロック様であり、これを粉砕して
も粒形は不揃いで、また矯味矯臭という点でも製剤上問
題がある。従って菌ペーストは乾燥する前に何等かの賦
型剤と液状もしくは泥状の状態で練合均質化した後に乾
燥するのが望ましい。Generally, the butyric acid bacterium paste harvested from the culture solution of butyric acid bacterium by the centrifugal separation method has a grayish brown irregular block-like shape when dried in this state, and even if it is crushed, the grain shape is not uniform. There is also a problem in terms of formulation in terms of flavor and odor. Therefore, it is desirable that the fungal paste is kneaded and homogenized in a liquid or mud state with some type of excipient before being dried, and then dried.
【００１０】そこで、諸種の賦型剤と菌ペーストとを練
合し、その組成物の性状を検討したところ、グルコマン
ナンと酪酸菌ペーストとを練合した組成物が乳白色でき
わめて均質な細粒状を呈し、また、矯味矯臭の点でも改
善され、投与剤型として、さらには他の医薬品添加剤、
希釈剤等を加えて造粒しても良好に分散するなど、製剤
的にも優れていることが明らかとなった。Then, various types of excipients and fungal paste were kneaded, and the properties of the composition were examined. As a result, it was found that the composition obtained by kneading glucomannan and butyric acid bacteria paste was milky white and had a very uniform fine grain. In addition, as a dosage form, other pharmaceutical additives,
It became clear that it is excellent in terms of formulation as well, for example, it is well dispersed even if it is granulated by adding a diluent or the like.
【００１１】他方、酪酸菌のバイオアベイラビリティー
の観点から、その組成物について検討した。経口的に投
与された酪酸菌は胃内において、蛋白消化液ペプシンと
胃酸による低pH環境とに暴露されるが、芽胞として抵抗
性のある酪酸菌は死滅することなくここを通過し、十二
指腸に到達する。そこでpHが中性付近まで上昇し、食物
は各種の消化液により消化され、栄養に富んだ環境が作
られた後、酪酸菌は発芽増殖の機会を得る。しかしなが
ら、そこでは多数の常在菌が栄養が奪い合い、互いに拮
抗し、いわゆる腸内ミクロフローラを形成している。こ
のような環境下において、酪酸菌は発芽増殖し、薬理作
用の発現可能なポピュレーションに達することが要求さ
れる。大量投与されれば作用も増強されるが、投与量に
も限界がある。そこで、他の常在菌には資化されず、酪
酸菌のみに特異的に資化される選択的利用性のある成分
を配合することによって、酪酸菌のみのポピュレーショ
ンの増大をもたらす。すなわち、薬理作用を増強するこ
とを目的として、当該組成物について検討を加えた。On the other hand, the composition of the butyric acid bacterium was examined from the viewpoint of bioavailability. Orally administered butyric acid bacteria are exposed in the stomach to the low pH environment of protein digestive fluid pepsin and gastric acid, but butyric acid bacteria, which are resistant to spores, pass through here without dying and enter the duodenum. To reach. There, the pH rises to near neutrality, the food is digested by various digestive fluids, and a nutrient-rich environment is created. However, there, a large number of indigenous bacteria compete with each other for nutrition and antagonize each other to form so-called intestinal microflora. Under these circumstances, butyric acid bacteria are required to germinate and proliferate and reach a population capable of expressing a pharmacological action. The effect is enhanced when a large amount is administered, but the dose is limited. Therefore, by incorporating a component having selective availability that is not assimilated by other indigenous bacteria but is specifically assimilated by butyric acid bacteria, the population of only butyric acid bacteria is increased. That is, the composition was examined for the purpose of enhancing the pharmacological action.
【００１２】まず、人糞便より、光岡らの方法に従っ
て、Escherichia, Klebsiella などのEnterobacteriace
ae, Enterococcus, Lactobacillus, Bifidobacterium,
Eubacterium,Bacteroidaceae, Peptococcaceae, Veillo
nella,Megasphaera, Clostridium等の腸内細菌を分離し
た。これら腸内細菌が増殖可能な液体培地において、糖
成分の代わりにグルコマンナンを添加した培地をそれぞ
れ調製し、各腸内細菌のグルコマンナン利用性について
検討した。その結果、各種腸内細菌のうち、当該酪酸菌
クロストリジウム・ブチリカムのみが良好にグルコマン
ナンを資化することが明らかとなった。First, according to the method of Mitsuoka et al. From human feces, Enterobacteriace such as Escherichia, Klebsiella, etc.
ae, Enterococcus, Lactobacillus, Bifidobacterium,
Eubacterium, Bacteroidaceae, Peptococcaceae, Veillo
Intestinal bacteria such as nella, Megasphaera and Clostridium were isolated. In these liquid media in which the intestinal bacteria can grow, media in which glucomannan was added instead of the sugar component were prepared, and the utilization of glucomannan by each intestinal bacterium was examined. As a result, it was revealed that among the various intestinal bacteria, only the butyric acid bacterium Clostridium butyricum favorably assimilates glucomannan.
【００１３】また、実際に人糞便中において、選択的に
酪酸菌が増殖するかどうか観察するために、糞便懸濁液
を調製し、これにコーンスターチもしくはグルコマンナ
ンを添加し酪酸菌を接種、培養した結果、グルコマンナ
ン添加液は、対照のコーンスターチ添加液と比較して、
pHは著名に低下し、酪酸菌が増殖していることが観察さ
れた。Further, in order to observe whether butyric acid bacteria selectively grow in human feces, a fecal suspension was prepared, and corn starch or glucomannan was added to this to inoculate and culture the butyric acid bacteria. As a result, the glucomannan additive solution was compared with the control corn starch additive solution,
The pH was markedly decreased and it was observed that butyric acid bacteria were growing.
【００１４】さらに、グルコマンナンを３日間自由に摂
取させたマウスに酪酸菌を投与し、その腸管内容物中の
酪酸菌の菌数を調べたところ、グルコマンナン摂取マウ
スの方が非摂取マウスよりも腸内の酪酸菌の菌数の多い
ことが確認された。これらの実験結果は、消化管内にお
いてグルコマンナンが常在腸内細菌により資化されず、
併用した酪酸菌のみに選択的に資化され、グルコマンナ
ンと酪酸菌とを配合した組成物は、そのポピュレーショ
ンの増大をもたらしめることを示している。Furthermore, when the butyric acid bacterium was administered to a mouse which was allowed to freely ingest glucomannan for 3 days, and the number of butyric acid bacteria in the intestinal contents of the mouse was examined, it was found that the mice ingested glucomannan were better than those not ingested. It was also confirmed that the number of butyric acid bacteria in the intestine was high. The results of these experiments indicate that glucomannan is not assimilated by resident intestinal bacteria in the digestive tract,
It is shown that the composition that is selectively assimilated only to the butyric acid bacterium used in combination and that contains glucomannan and butyric acid bacterium can increase the population.
【００１５】以上、製剤学的もしくは、バイオアベイラ
ビリティーの観点からみて本組成物は優れた特徴をも
つ。As described above, the present composition has excellent characteristics from the viewpoint of pharmaceutical or bioavailability.
【００１６】なお、この組成物の良好な配合割合（重
量）は、菌ペースト１重量部に対して、グルコマンナン
０．１〜１０００重量部、とくに０．２から１０重量部
までが最適であるが、目的とする菌濃度に応じて調製す
るには、グルコマンナン量を適宜増減することが可能で
ある。The optimum blending ratio (weight) of this composition is 0.1 to 1000 parts by weight of glucomannan, particularly 0.2 to 10 parts by weight, based on 1 part by weight of the bacterial paste. However, the amount of glucomannan can be appropriately increased or decreased in order to prepare it according to the desired bacterial concentration.
【００１７】この組成物を例えば、医薬品として用いる
場合の剤型は、このままでも用いられるが散剤、顆粒
剤、細粒剤、錠剤、糖衣錠剤、カプセル剤、エンテリッ
クコーティング剤等に製剤化してもよい。希釈剤には、
一般の医薬品製剤に使用される賦形剤、結合剤、崩壊剤
等が用いられ、これに加えて着色剤、矯味剤、安定化
剤、保存剤、滑沢剤等を添加しても良い。The dosage form of this composition for use as a medicine can be used as it is, but it can be formulated into powders, granules, fine granules, tablets, sugar-coated tablets, capsules, enteric coating agents and the like. Good. Diluents include
Excipients, binders, disintegrants and the like used in general pharmaceutical preparations are used, and in addition thereto, coloring agents, corrigents, stabilizers, preservatives, lubricants and the like may be added.
【００１８】機能性食品用としては、このままでも用い
られるが、他の食物繊維、オリゴサッカライド、穀物
類、ビタミン類等を加え、さらに、フレーバー、着色
剤、矯味剤等を加え、食に適した形態に形成加工するこ
とも可能である。Although it can be used as it is for functional foods, it is suitable for food by adding other dietary fibers, oligosaccharides, grains, vitamins and the like, and further adding flavors, coloring agents, flavoring agents and the like. It is also possible to form and process the shape.
【００１９】また、動物用としては、このままでも用い
られるが、人向けと同様に各種賦形剤、添加剤を加え、
同様の剤型としても用いられる。とうもろこし粉、大豆
かす、大麦粉、裸麦粉、大豆粉、米ぬか、脱脂米ぬか、
もみがら、ばれいしょ粉、かんしょ粉、豆腐かす、デン
プン、酵母、魚粉等の家畜飼料に配合し、用いることも
可能である。Although it can be used as it is for animals, various excipients and additives are added in the same manner as for humans.
It is also used as a similar dosage form. Corn flour, soybean meal, barley flour, naked wheat flour, soybean flour, rice bran, defatted rice bran,
It is also possible to mix and use it in livestock feed such as chaff, potato powder, taro powder, tofu dregs, starch, yeast and fish meal.
【００２０】投与量については、菌数として一日当たり
１×１０6 〜１×１０10個の範囲が適当であるが、患者
の年齢、疾患の症状に応じて、また、機能性食品用、動
物用はそれぞれ目的に応じて、適宜、増減が可能であ
る。投与方法は、医薬品では１日、１回〜３回食後に服
用することが好ましいが、適宜服用することも可能であ
る。機能性食品用、動物用では、１日１回〜数回自由に
摂取して良い。The dosage is appropriately in the range of 1 × 10 6 to 1 × 10 10 cells per day, but depending on the age of the patient, the symptoms of the disease, and for functional foods and animals. The usage can be increased or decreased depending on the purpose. As for the administration method, it is preferable to take the medicine once a day or three times after meals, but it is also possible to take it appropriately. For functional foods and animals, they can be taken freely once to several times a day.
【００２１】[0021]
実施例１ 酪酸菌とグルコマンナンとの組成物の調製は次のように
行った。既知のCS培地（特開昭５９−１８７７８４）に
よって培養した酪酸菌（クロストリジウム ブチリカム
ミヤイリ ５８８）の菌ペースト１００ｇにグルコマ
ンナン１００ｇを添加し、練合機で均一になるまで練合
した。次に棚式真空乾燥機により５０℃下、５時間、真
空乾燥（１０ｍｍＨｇ）を行った。得られた乾燥物は粉
砕機により粉砕して該組成物を得た。該組成物は乳白色
で均質な細粒状でほとんど無味無臭であった。なお、本
組成物中の生菌数は１．８×１０10個／ｇであった。Example 1 A composition of butyric acid bacterium and glucomannan was prepared as follows. 100 g of glucomannan was added to 100 g of a butyric acid bacterium (Clostridium butyricum Miyairi 588) bacterial paste cultivated in a known CS medium (Japanese Patent Laid-Open No. 59-187784) and kneaded with a kneader until uniform. Next, vacuum drying (10 mmHg) was performed at 50 ° C. for 5 hours using a shelf vacuum dryer. The obtained dried product was pulverized with a pulverizer to obtain the composition. The composition was milky white, uniform fine granules, and had almost no taste and odor. The viable cell count in this composition was 1.8 × 10 10 cells / g.
【００２２】実施例２ 人糞便中より、EnterobacteriaceaeはDHL agar, TS aga
r 培地を、EnterococcusはTATAC agar, TSagar培地を、
Lactobacillus はLBS agar, BL agar 培地を、Bifidoba
cterium はBS agar,BL agar, EG agar培地を、Eubacter
ium はES agar,BL agar,EG agar 培地を、Bacteroidace
aeはNBGT agar, BL agar, EG agar 培地を、Peptococca
ceaeはBL agar, EG agar培地を、Veillonella ならびに
Megasphaera はVS agar, BL agar, EG agar 培地を、Cl
ostridium はBL agar, EG agar培地をそれぞれ使用し分
離した。これらの分離菌は次の培地を用い、グルコマン
ナンの資化試験に供した。判定は、培養終了後の酸の産
生を、pHを測定することにより行った。 GAM 糖分解用半流動培地 ５２．５ｇ グルコマンナンorグルコース ５ｇ 精製水 １０００ｍｌExample 2 From the human feces, Enterobacteriaceae showed DHL agar, TS aga
r medium, Enterococcus is TATAC agar, TSagar medium,
Lactobacillus was prepared from LBS agar, BL agar medium and Bifidoba
For cterium, use BS agar, BL agar, EG agar medium with Eubacter
ium is ES agar, BL agar, EG agar medium, Bacteroidace
ae is NBGT agar, BL agar, EG agar medium, Peptococca
ceae was BL agar, EG agar medium, Veillonella and
Megasphaera is VS agar, BL agar, EG agar medium, Cl
The ostridium was separated using BL agar and EG agar media, respectively. These isolates were subjected to a glucomannan assimilation test using the following medium. The determination was carried out by measuring the pH of the acid produced after the culture was completed. GAM Glycolysis semi-fluid medium 52.5g Glucomannan or glucose 5g Purified water 1000ml
【００２３】さらに、酪酸菌の二株クロストリジウム・
ブチリカム・ミヤイリ５８８，C,butyricum NIP １００
６，その他同属の標準株であるC. pasteurianum ATCC６
０１３，C.beijerinckii ATCC ２５７５２，C.acetobut
ylicum IAM１９０１２については、次の培地をグルコマ
ンナン資化試験に用いた。 カシトン １５ｇ イーストエキス １ｇ 塩化ナトリウム ２．５ｇ L-シスチン塩酸塩 ０．０５ｇ チオグリコール酸ナトリウム ０．５ｇ グルコマンナン又はグルコース ５ｇ 精製水 １０００ｍｌFurthermore, two strains of butyric acid bacteria Clostridium
Butyricum Miyairi 588, C, butyricum NIP 100
6, C. pasteurianum ATCC6 which is another standard strain of the same genus
013, C. beijerinckii ATCC 25752, C. acetobut
For ylicum IAM19012, the following medium was used for the glucomannan utilization test. Kashiton 15 g Yeast extract 1 g Sodium chloride 2.5 g L-cystine hydrochloride 0.05 g Sodium thioglycolate 0.5 g Glucomannan or glucose 5 g Purified water 1000 ml
【００２４】なお、当該菌による資化能の判定は３７
℃、３日間の培養後、BCP 又はBTB を加えることにより
調べた。The assimilation capacity of the bacterium is 37
After culturing at 3 ° C for 3 days, it was examined by adding BCP or BTB.
【００２５】その結果、表−１に示すようにグルコース
添加培地では、すべての被検菌において良好な増殖が認
められた。しかしながら、グルコマンナン添加培地で
は、良好な増殖が認められたのは、クロストリジウム・
ブチリカム・ミヤイリ５８８とＣ．butyricum NIP １０
０６の２株のみであった。As a result, as shown in Table 1, in the glucose-containing medium, good growth was observed in all the test bacteria. However, in the glucomannan-added medium, good growth was observed in Clostridium
Buchirikum Miyairi 588 and C.I. butyricum NIP 10
There were only two strains of 06.
【００２６】[0026]
【表１】 [Table 1]
【００２７】実施例３ 健康な人の糞便０．５ｇを採取し、直ちに嫌気性グロー
ブボックス内で、０．０３％チオグリコール酸ナトリウ
ム添加PBS 30ｍｌに懸濁し糞便懸濁液を調製した。別に
同PBS ９ｍｌにスターチ０．３ｇもしくはグルコマンナ
ン０．３ｇをそれぞれ添加した液を調製し、これを糞便
懸濁液と等量混和した。これらの混和液に酪酸菌クロス
トリジウム・ブチリカム・ミヤイリ５８８を濃度５×１
０4/ｍｌになるように接種し、３７℃下、２４時間静置
培養を行った。なお、対照として上記糖類の添加してい
ない系についても同様の操作を行った。増殖の判定は被
検液のpH、発泡、検鏡を指標とした。結果は、表−２に
示す通り、対照のスターチ添加系と比べてグルコマンナ
ン添加系のほうがpH低下ならびに発泡が著しく、また検
鏡下、酪酸菌がメジャーであることが確認された。Example 3 Feces of 0.5 g of a healthy person were collected and immediately suspended in 30 ml of PBS containing 0.03% sodium thioglycolate in an anaerobic glove box to prepare a fecal suspension. Separately, a solution was prepared by adding 0.3 g of starch or 0.3 g of glucomannan to 9 ml of the same PBS, and mixed with the fecal suspension in the same amount. Butyric acid bacterium Clostridium butyricum Miyairi 588 was added to these mixed solutions at a concentration of 5 × 1.
The cells were inoculated at a rate of 0 4 / ml, and statically cultured at 37 ° C for 24 hours. As a control, the same operation was performed for the system to which the saccharide was not added. The proliferation was judged by using the pH, foaming and speculum of the test solution as indexes. As a result, as shown in Table 2, it was confirmed that the glucomannan-added system markedly lowered pH and foamed as compared with the control starch-added system, and that butyric acid bacteria were major under the microscope.
【００２８】[0028]
【表２】 [Table 2]
【００２９】実施例４ 給水にグルコマンナンを５％混和し、これを３日間自由
に摂取させた ICR系マウス（約３０ｇ）に、クロストリ
ジウム・ブチリカム・ミヤイリ５８８を一頭当り 3.1×
１０6 個、経口的に投与した。投与３時間、６時間後に
動物を屠殺に処し、全消化管を摘出し、嫌気性グローブ
ボックス内において、その内容物中のクロストリジウム
・ブチリカム・ミヤイリ５８８の生菌数を GAM平板培地
を用い測定した。なお、対照としてグルコマンナンを摂
取させていない系についても同様の操作を行った。結果
は表−３に示す通り、グルコマンナンを摂取させた動物
において、特に投与３時間後の菌数が対照に比較して多
かった。Example 4 Clostridium butyricum miyairi 588 was added to an ICR mouse (about 30 g) in which 5% of glucomannan was mixed in the water supply and which was freely ingested for 3 days to obtain 3.1 × per head.
10 6 were orally administered. The animals were sacrificed 3 hours and 6 hours after administration, the entire digestive tract was excised, and the viable count of Clostridium butyricum Miyairi 588 in the contents was measured using a GAM plate medium in an anaerobic glove box. . As a control, the same operation was performed for a system in which glucomannan was not ingested. As shown in Table 3, the number of bacteria ingested glucomannan was higher than that of the control, particularly 3 hours after the administration.
【００３０】[0030]
【表３】 [Table 3]
【００３１】[0031]
【発明の効果】本発明の酪酸菌組成物によれば、製剤的
に優れ、かつバイオアベイラビリティーの観点からも、
優れた特徴をもつ組成物を提供することができる。EFFECTS OF THE INVENTION According to the butyric acid bacterium composition of the present invention, it is excellent in terms of formulation and also from the viewpoint of bioavailability.
It is possible to provide a composition having excellent characteristics.
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.6 識別記号 庁内整理番号 ＦＩ 技術表示箇所 Ａ６１Ｋ 47/36 Ｊ ─────────────────────────────────────────────────── ─── Continuation of the front page (51) Int.Cl. 6 Identification code Internal reference number FI technical display area A61K 47/36 J
Claims (2)
マンナンとからなる酪酸菌組成物。1. A butyric acid bacterium composition comprising a viable intestinal bacterium represented by butyric acid bacterium and glucomannan.
・ミヤイリ５８８である請求項（１）に記載の酪酸菌組
成物。2. The butyric acid bacterium composition according to claim 1, wherein the butyric acid bacterium is Clostridium butyricum Miyairi 588.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP3169965A JPH07145A (en) | 1991-07-10 | 1991-07-10 | Composition of butyric acid bacterium |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP3169965A JPH07145A (en) | 1991-07-10 | 1991-07-10 | Composition of butyric acid bacterium |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH07145A true JPH07145A (en) | 1995-01-06 |
Family
ID=15896107
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP3169965A Pending JPH07145A (en) | 1991-07-10 | 1991-07-10 | Composition of butyric acid bacterium |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH07145A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001292728A (en) * | 2000-04-13 | 2001-10-23 | Enajikku Kk | Obesity-preventive food |
| WO2007114378A1 (en) | 2006-03-31 | 2007-10-11 | Nippon Paper Chemicals Co., Ltd. | Composition for beverage or food |
| CN109561725A (en) * | 2016-06-10 | 2019-04-02 | N·V·努特里奇亚 | Allergic risk and nutrients for reducing the risk |
-
1991
- 1991-07-10 JP JP3169965A patent/JPH07145A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001292728A (en) * | 2000-04-13 | 2001-10-23 | Enajikku Kk | Obesity-preventive food |
| WO2007114378A1 (en) | 2006-03-31 | 2007-10-11 | Nippon Paper Chemicals Co., Ltd. | Composition for beverage or food |
| CN109561725A (en) * | 2016-06-10 | 2019-04-02 | N·V·努特里奇亚 | Allergic risk and nutrients for reducing the risk |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1010372B1 (en) | Bakery products comprising live lyophilised lactic bacteria | |
| EP1675617B1 (en) | Compositions for augmenting kidney function | |
| KR20050057259A (en) | Probiotic bacterium : lactobacillus fermentum | |
| KR101992537B1 (en) | Novel Lactobacillus sakei and compositions comprising the same | |
| CN112716982B (en) | Lactic acid bacteria-containing composition and use thereof | |
| CN113855712B (en) | Composition capable of promoting defecation and application thereof | |
| JPH0656680A (en) | Nutritional and/or pharmaceutical composi- tion containing freeze-dried lactic acid bacterium and preparation and use thereof | |
| KR101492650B1 (en) | Agent for accelerating the increase in and/or preventing the decrease in blood adiponectin level, and visceral fat accumulation inhibitor | |
| EP3202892A1 (en) | Uses of bacteroides in treatment or prevention of obesity-related diseases | |
| CN109419816B (en) | Application of bacteroides cellulolyticus in preventing and/or treating heart diseases | |
| CN109315769A (en) | It is a kind of for improving the composition and preparation method thereof of human body enteral environment | |
| CN106974262B (en) | Application of intestinal probiotic bacillus in treating and preventing obesity and related diseases | |
| CA2812909C (en) | Compositions and methods for augmenting kidney function | |
| CN113750113B (en) | Composition of probiotics and prebiotics and application thereof | |
| JPH03151854A (en) | Composition for improving intestinal environment | |
| JP2002223727A (en) | Functional food | |
| KR20110116344A (en) | Composition for improving bowel function and relieving constipation containing dietary fiber, oligosaccharide and bacillus coagulans | |
| CN107002023B (en) | Use of bacteroides in the treatment or prevention of obesity related diseases | |
| CN112931883A (en) | Prebiotic composition and preparation method and application thereof | |
| CN110869035B (en) | Application of African adequacy bacterium to preparation of composition for preventing and/or treating lipid metabolism related diseases | |
| CN106889615B (en) | Microelement selenium dietary supplement with function of regulating intestinal flora and application thereof | |
| JPH07145A (en) | Composition of butyric acid bacterium | |
| TW201822649A (en) | Composition for improving intestinal flora | |
| CN114191447A (en) | Application of hyaluronic acid and salt thereof in improving intestinal flora disorder and composition thereof | |
| CN106974940B (en) | Application of probiotics of scleritis in treating and preventing obesity and related diseases |